Bausch + Lomb Sets 2027 Start for Dry AMD Program
Bausch + Lomb announced an FDA meeting clarified the clinical path for BL1243 (tonabersat), an oral dry AMD candidate, and the company plans to initiate its clinical program in 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.